J Philippe1, P Stijnen2, D Meyre3, F De Graeve1, D Thuillier1, J Delplanque1, G Gyapay4, O Sand1, J W Creemers2, P Froguel5, A Bonnefond1. 1. 1] CNRS-UMR8199, Institut de Biologie de Lille, Lille Pasteur Institute, Lille, France [2] Lille 2 University, Lille, France [3] European Genomic Institute for Diabetes (EGID), Lille, France. 2. Laboratory for Biochemical Neuroendocrinology, Department of Human Genetics, KU Leuven, Leuven, Belgium. 3. 1] CNRS-UMR8199, Institut de Biologie de Lille, Lille Pasteur Institute, Lille, France [2] Lille 2 University, Lille, France [3] European Genomic Institute for Diabetes (EGID), Lille, France [4] Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada. 4. Genoscope, Evry, France. 5. 1] CNRS-UMR8199, Institut de Biologie de Lille, Lille Pasteur Institute, Lille, France [2] Lille 2 University, Lille, France [3] European Genomic Institute for Diabetes (EGID), Lille, France [4] Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, London, United Kingdom.
Abstract
BACKGROUND: A significant proportion of severe familial forms of obesity remain genetically elusive. Taking advantage of our unique cohort of multigenerational obese families, we aimed to assess the contribution of rare mutations in 29 common obesity-associated genes to familial obesity, and to evaluate in these families the putative presence of nine known monogenic forms of obesity. METHODS: Through next-generation sequencing, we sequenced the coding regions of 34 genes involved in polygenic and/or monogenic forms of obesity in 201 participants (75 normal weight individuals, 54 overweight individuals and 72 individuals with obesity class I, II or III) from 13 French families. In vitro functional analyses were performed to investigate the mutation PCSK1-p.Arg80* which was identified in a family. RESULTS: A novel heterozygous nonsense variant in PCSK1 (p.Arg80*), encoding a propeptide truncated to less than two exons (out of 14), was found to co-segregate with obesity in a three-generation family. We demonstrated that this mutation inhibits PCSK1 enzyme activity and that this inhibition most likely does not involve a strong physical interaction. Furthermore, both mutations PCSK1-p.Asn180Ser and POMC-p.Phe144Leu, which had previously been reported to be associated with severe obesity, were also identified in this study, but did not co-segregate with obesity. Finally, we did not identify any rare mutations co-segregating with obesity in common obesity susceptibility genes, except for CADM2 and QPCTL, where we found two novel variants (p.Arg81His and p.Leu98Pro, respectively) in three obese individuals. CONCLUSIONS: We showed for the first time that a nonsense mutation in PCSK1 was likely to cause dominantly inherited human obesity, due to the inhibiting properties of the propeptide fragment encoded by the null allele. Furthermore, the present family sequencing design challenged the contribution of previously reported mutations to monogenic or at least severe obesity.
BACKGROUND: A significant proportion of severe familial forms of obesity remain genetically elusive. Taking advantage of our unique cohort of multigenerational obese families, we aimed to assess the contribution of rare mutations in 29 common obesity-associated genes to familial obesity, and to evaluate in these families the putative presence of nine known monogenic forms of obesity. METHODS: Through next-generation sequencing, we sequenced the coding regions of 34 genes involved in polygenic and/or monogenic forms of obesity in 201 participants (75 normal weight individuals, 54 overweight individuals and 72 individuals with obesity class I, II or III) from 13 French families. In vitro functional analyses were performed to investigate the mutation PCSK1-p.Arg80* which was identified in a family. RESULTS: A novel heterozygous nonsense variant in PCSK1 (p.Arg80*), encoding a propeptide truncated to less than two exons (out of 14), was found to co-segregate with obesity in a three-generation family. We demonstrated that this mutation inhibits PCSK1 enzyme activity and that this inhibition most likely does not involve a strong physical interaction. Furthermore, both mutations PCSK1-p.Asn180Ser and POMC-p.Phe144Leu, which had previously been reported to be associated with severe obesity, were also identified in this study, but did not co-segregate with obesity. Finally, we did not identify any rare mutations co-segregating with obesity in common obesity susceptibility genes, except for CADM2 and QPCTL, where we found two novel variants (p.Arg81His and p.Leu98Pro, respectively) in three obese individuals. CONCLUSIONS: We showed for the first time that a nonsense mutation in PCSK1 was likely to cause dominantly inherited human obesity, due to the inhibiting properties of the propeptide fragment encoded by the null allele. Furthermore, the present family sequencing design challenged the contribution of previously reported mutations to monogenic or at least severe obesity.
Authors: Martin Fugère; Polizois C Limperis; Véronique Beaulieu-Audy; Frédéric Gagnon; Pierre Lavigne; Klaus Klarskov; Richard Leduc; Robert Day Journal: J Biol Chem Date: 2001-11-26 Impact factor: 5.157
Authors: Michael Benzinou; John W M Creemers; Helene Choquet; Stephane Lobbens; Christian Dina; Emmanuelle Durand; Audrey Guerardel; Philippe Boutin; Beatrice Jouret; Barbara Heude; Beverley Balkau; Jean Tichet; Michel Marre; Natascha Potoczna; Fritz Horber; Catherine Le Stunff; Sebastien Czernichow; Annelli Sandbaek; Torsten Lauritzen; Knut Borch-Johnsen; Gitte Andersen; Wieland Kiess; Antje Körner; Peter Kovacs; Peter Jacobson; Lena M S Carlsson; Andrew J Walley; Torben Jørgensen; Torben Hansen; Oluf Pedersen; David Meyre; Philippe Froguel Journal: Nat Genet Date: 2008-07-06 Impact factor: 38.330
Authors: Robert S Jackson; John W M Creemers; I Sadaf Farooqi; Marie-Laure Raffin-Sanson; Andrea Varro; Graham J Dockray; Jens J Holst; Patricia L Brubaker; Pierre Corvol; Kenneth S Polonsky; Diane Ostrega; Kenneth L Becker; Xavier Bertagna; John C Hutton; Anne White; Mehul T Dattani; Khalid Hussain; Stephen J Middleton; Thomasina M Nicole; Peter J Milla; Keith J Lindley; Stephen O'Rahilly Journal: J Clin Invest Date: 2003-11 Impact factor: 14.808
Authors: Walter D Park; John F O'Brien; Patrick A Lundquist; Daniel L Kraft; Cate Walsh Vockley; Pamela S Karnes; Marc C Patterson; Karen Snow Journal: Hum Mutat Date: 2003-10 Impact factor: 4.878
Authors: P Stijnen; B Brouwers; E Dirkx; B Ramos-Molina; L Van Lommel; F Schuit; L Thorrez; J Declercq; J W M Creemers Journal: Int J Obes (Lond) Date: 2016-01-20 Impact factor: 5.095
Authors: M I Cooiman; L Kleinendorst; E O Aarts; I M C Janssen; H K Ploos van Amstel; A I Blakemore; E J Hazebroek; H J Meijers-Heijboer; B van der Zwaag; F J Berends; M M van Haelst Journal: Obes Surg Date: 2020-02 Impact factor: 4.129
Authors: Omar Ali; Diana Cerjak; Jack W Kent; Roland James; John Blangero; Melanie A Carless; Yi Zhang Journal: Clin Epigenetics Date: 2015-02-20 Impact factor: 6.551
Authors: Dennis Löffler; Susanne Behrendt; John W M Creemers; Jürgen Klammt; Gabriela Aust; Juraj Stanik; Wieland Kiess; Peter Kovacs; Antje Körner Journal: Mol Metab Date: 2016-12-08 Impact factor: 7.422